623142-96-1
623142-96-1 结构式
基本信息
N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]-2-甲氧基苯基]-N'-[1-(2-噻唑基)乙基]脲
CS-1094
KI20227
KI 20227
KI20227
KI-20227
KI 20227
1-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)-2-methoxyphenyl)-3-(1-(thiazol-2-yl)ethyl)urea
N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]urea
1-[4-(6,7-dimethoxyquinolin-4-yl)oxy-2-methoxyphenyl]-3-[1-(1,3-thiazol-2-yl)ethyl]urea
Urea, N-[4-[(6,7-diMethoxy-4-quinolinyl)oxy]-2-Methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]-
物理化学性质
常见问题列表
N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]-2-甲氧基苯基]-N'-[1-(2-噻唑基)乙基]脲是一种 c-fms 酪氨酸激酶抑制剂，可在骨转移模型中抑制破骨细胞分化和溶骨性骨破坏。
| Target | Value |
|
c-Fms
(Cell-free assay) | 2 nM |
|
VEGFR2
(Cell-free assay) | 12 nM |
|
PDGFRβ
(Cell-free assay) | 217 nM |
|
c-Kit
(Cell-free assay) | 451 nM |
Ki20227 (0.1-1000 nM; 72 hours) with 100 and 1,000 nM almost suppresses M-NFS-60 cell growth and HUVEC cell growth, respectively.
Ki20227 (0.1-1000 nM; 1 hour) suppresses M-CSF-dependent c-Fms phosphorylation in a dose-dependent manner.
Cell Viability Assay
| Cell Line: | M-NFS-60 cells, HUVEC cells, human A375 melanoma cells |
| Concentration: | 0.1, 0.3, 1, 3, 10, 30, 100, 300, 1000 nM |
| Incubation Time: | 72 hours |
| Result: | 100 and 1,000 nM almost suppressed M-NFS-60 cell growth and HUVEC cell growth, respectively. |
Cell Viability Assay
| Cell Line: | RAW264.7 cell lysate |
| Concentration: | 0.1, 0.3, 1, 3, 10, 30, 100, 300, 1000 nM |
| Incubation Time: | 1 hour |
| Result: | Suppressed M-CSF-dependent c-Fms phosphorylation in a dose-dependent manner. |
Ki20227 (orally;10-50 mg/kg/d for 20 days) of 50 mg/kg/d of Ki20227 for 20 days markedly decreases the osteolytic lesion areas.
ki20227 during global ischemia led to a significant deficit in microglial density in the CNS in mice, and CSF1R-inhibition led to a significant reduction in the neuronal density of mice.
| Animal Model: | 4-week-old male F344/NJcl-rnu rats |
| Dosage: | 10, 20, and 50 mg/kg |
| Administration: | Orally; once per day for 20 days |
| Result: | Oral administration of 50 mg/kg/d markedly decreased the osteolytic lesion areas. |
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/04/30 | HY-10408 | N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]-2-甲氧基苯基]-N'-[1-(2-噻唑基)乙基]脲 Ki20227 | 623142-96-1 | 2mg | 820元 |
| 2024/04/30 | S7688 | N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]-2-甲氧基苯基]-N'-[1-(2-噻唑基)乙基]脲 Ki20227 | 623142-96-1 | 2mg | 1170.64元 |
| 2024/04/30 | HY-10408 | N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]-2-甲氧基苯基]-N'-[1-(2-噻唑基)乙基]脲 Ki20227 | 623142-96-1 | 5mg | 1400元 |